Phase III Study to Evaluate the Efficacy and Safety of AD-209
Phase 3
Recruiting
- Conditions
- Hypertension,Essential
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT06348576
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of AD-224
Phase 3
Recruiting
- Conditions
- Hypertension,Essential
- Interventions
- Drug: AD-224CDrug: Placebo of AD-224BDrug: Placebo of AD-224ADrug: Placebo of AD-224C
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT06291207
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of AD-223
Phase 3
Completed
- Conditions
- Hypertension,Essential
- Interventions
- Drug: AD-223B PlaceboDrug: AD-223A PlaceboDrug: AD-223C Placebo
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 502
- Registration Number
- NCT06052748
- Locations
- 🇰🇷
Hanyang University Hospital, Seoul, Korea, Republic of
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121
Phase 1
Completed
- Conditions
- Gastro Esophageal Reflux
- Interventions
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06025773
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Assess the Safety and Pharmacokinetics of AD-104-A
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05703282
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of AD-209
Phase 2
Completed
- Conditions
- Hypertension, Essential
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 221
- Registration Number
- NCT05631990
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of AD-218
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 520
- Registration Number
- NCT05400317
- Locations
- 🇰🇷
Yeongnam University Hospital, Daegu, Nam-gu, Korea, Republic of
A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05202405
- Locations
- 🇰🇷
H+ Yangji Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A
Phase 3
Completed
- Conditions
- Primary Hypercholesterolemia
- Interventions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 290
- Registration Number
- NCT05131997
- Locations
- 🇰🇷
Yonsei University Hospital, Seoul, Seodaemun-gu, Korea, Republic of
A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091
Phase 1
Completed
- Conditions
- Embolism and Thrombosis
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT05128591
- Locations
- 🇰🇷
H+ Yangji Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath